A more active early enteral nutrition policy in Sweden was associated with faster feeding advancement, earlier fortification, increased protein intake, and improved growth without increased NEC risk.
This retrospective cohort study evaluated the patient characteristics, healthcare utilization, and healthcare costs among patients with MASH with and without metabolic syndrome, obesity, and type 2 diabetes/elevated fasting glucose.
Highly processed foods are generally considered unhealthy. But the potential risks for diabetes and CVDs depend heavily on specific product types.
Sugar, fibre, protein, fat, alcohol; many components of our diet affect our gastrointestinal tract lining. A new review explains what this means for gut health.
A deeper understanding of the factors influencing survival in patients with pancreatic ductal adenocarcinoma (PDAC) is essential for optimizing treatment strategies. This study investigates the independent association of body composition parameters with overall survival in patients with PDAC.
This study integrates targeted delivery, antioxidant therapy, and microbiota modulation, offering an effective strategy for precision IBD treatment.
Risankizumab, a monoclonal antibody targeting interleukin-23, is approved for the treatment of Crohn’s disease (CD). Real-world evidence on its effectiveness remains limited. We assessed 1-year effectiveness and safety of risankizumab in a prospective cohort of patients with CD, emphasizing difficult-to-treat disease.
This international randomized clinical trial, including 188 patients with LAPC after 2 months of multiagent chemotherapy, found that local ablative therapy with RFA did not improve survival compared with chemotherapy only and worsened quality of life.
Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Collectively, these findings suggest that Aβ promotes gut symptoms through alteration of ENS connectivity and butyrate counteracts these impairments with an amelioration of neuroinflammation and memory function in AD model.
Treatment with semaglutide can lead to weight loss in obese patients – but according to US data, it significantly increases the risk of gastroparesis.
GIB in patients with CV disease is independently associated with subsequent morbidity and mortality. Patterns in antithrombotic resumption were associated with outcomes. Further research into optimal antithrombotic management following GIB is essential.
This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and therapeutic interventions.
This retrospective study included 380 hospitalized cirrhotic patients complicated by PVT, categorized into bleeding and non-bleeding groups based on history of gastrointestinal bleeding.
Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure.
A study saw less frequent severe liver complications in MASLD patients treated with SGLT-2 inhibitors, compared to glitazones treatments, but not less than GLP-1 receptor agonists treatments.
Prior cancer was independently associated with poorer overall and cancer-specific survival and with prior stomach, head and neck, or lung cancers; the negative association with survival was also found when the prior cancer occurred more than 5 years before ESCC diagnosis.
Patients with CIPO underwent genomic profiling, including NGS panel, long-range PCR, whole-exome, and whole-genome sequencing. Centralized histological analysis of full-thickness bowel biopsies and resections was integrated with genomic data to assess their combined impact on disease outcomes.
New data shows that the widely used sweetener sucralose can impair the response to PD-1-based immunotherapies in tumor patients, due to triggered changes in the gut microbiome.
A systematic review examines the question of whether targeted respiratory muscle training can influence the anti-reflux barrier and alleviate reflux symptoms.